APA (7th ed.) Citation

Xu, P., Luo, W., Hu, J., Ma, X., Hao, Q., Hui, W., . . . Kang, H. (2024). Favorable outcome of neoadjuvant endocrine treatment than surgery‐first in female HR‐positive/HER2‐negative breast cancer patients—A NCDB analysis (2010–2016). Cancer Medicine, 13(11), 1. https://doi.org/10.1002/cam4.7244

Chicago Style (17th ed.) Citation

Xu, Peng, et al. "Favorable Outcome of Neoadjuvant Endocrine Treatment than Surgery‐first in Female HR‐positive/HER2‐negative Breast Cancer Patients—A NCDB Analysis (2010–2016)." Cancer Medicine 13, no. 11 (2024): 1. https://doi.org/10.1002/cam4.7244.

MLA (9th ed.) Citation

Xu, Peng, et al. "Favorable Outcome of Neoadjuvant Endocrine Treatment than Surgery‐first in Female HR‐positive/HER2‐negative Breast Cancer Patients—A NCDB Analysis (2010–2016)." Cancer Medicine, vol. 13, no. 11, 2024, p. 1, https://doi.org/10.1002/cam4.7244.